Patel, Jignesh; Churchwell, Mariann D; Seroogy, Julie D; Barriere, Steven L; Grio, Maricor; Mueller, Bruce A
description
Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States. Telavancin's parenteral solution contains hydroxy propyl-beta -cyclodextrin (HP-beta -CD) to enhance its solubility. The disposition of telavancin and HP-beta -CD during continuous renal replacement therapies (CRRT ) has not been previously reported.
